Evidence map›Paper›PMID 40899949›Full record

ArticleJAMA2025

Transparent Reporting of Observational Studies Emulating a Target Trial-The TARGET Statement.

Aidan G Cashin, Harrison J Hansford, Miguel A Hernán, Sonja A Swanson, Hopin Lee, Matthew D Jones, Issa J Dahabreh, Barbra A Dickerman, Matthias Egger, Xabier Garcia-Albeniz and 10 more

2 registry-linked trialsAbstract read
In one paragraph

Article in JAMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07465926. Cited by 111 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07465926 completed

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Ran2017Enrolled451,036Registered outcomes12Posted comparisons0ConditionsCardiovascular Disease Risk Factor, Cardiovascular-kidney-metabolic Syndrome, Kidney Disease, Obesity & OverweightArmsGLP-1 receptor agonist, SGLT2 inhibitor
Open the trial in the graph
NCT07512401 completednot on this map

Safety of Reduced Methotrexate Lab Monitoring: a Population-based, Target Trial Emulation Study

TypeobservationalSponsorMayo ClinicRan2012 to 2025Enrolled2,414ConditionsRheumatic DiseasesArmsStandard methotrexate lab monitoring, Reduced methotrexate lab monitoring
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Comparative effectiveness of posterior cervical foraminotomy versus anterior cervical discectomy with fusion for single-level cervical radiculopathy: a target trial emulation study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Aidan G CashinCentre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
Harrison J HansfordCentre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
Miguel A HernánCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Sonja A SwansonCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Hopin LeeUniversity of Exeter Medical School, Exeter, United Kingdom.
Matthew D JonesCentre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
Issa J DahabrehCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Barbra A DickermanCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Matthias EggerInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Xabier Garcia-AlbenizCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Robert M GolubDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Nazrul IslamOxford Population Health, Big Data Institute, University of Oxford, Oxford, United Kingdom.
Sara LodiCAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Margarita Moreno-BetancurClinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Australia.
Sallie-Anne PearsonNHMRC Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Melissa K SharpDepartment of Public Health and Epidemiology, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Jonathan A C SterneDepartment of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Elizabeth A StuartDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
James H McAuleyCentre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.

Funding

Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
Use of Registries, Claims and Health System Data to Enhance the Evaluation of Cardiovascular Therapies in Clinical TrialsR01HL136708 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Issa J. Dahabreh, Robert Yeh · 2017 to 2026
$6.9M
Dynamic Strategies for the clinical management of HIV diseaseR37AI102634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MIGUEL HERNAN · 2018 to 2026
$5.3M
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)R01HL141505 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G., WANG, SHIRLEY · 2019 to 2023
$3.6M
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populationsR01AR080194 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Sebastian G. Schneeweiss · 2022 to 2026
$3.3M
HIV-1 subtype-specific drug resistance in patients failing Dolutegravir-based 1st, 2nd or 3rd line regimens: the International epidemiological Databases to Evaluate AIDS (IeDEA)R01AI152772 · NIAID · UNIVERSITY OF ZURICH · PI Roger Dimitri Kouyos · 2021 to 2026
$3.2M
Combining data sources to identify effect moderation for personalized mental health treatmentR01MH126856 · NIMH · JOHNS HOPKINS UNIVERSITY · PI STUART, ELIZABETH A. · 2021 to 2024
$1.7M
Identifying optimal dynamic strategies for prostate cancer controlR00CA248335 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI DICKERMAN, BARBRA ANNE · 2022 to 2025
$688k
NCI NIH HHS R00 CA248335NHLBI NIH HHS R01 HL136708NHLBI NIH HHS R01 HL141505NIAID NIH HHS R01 AI152772NIAID NIH HHS R37 AI102634NIAID NIH HHS U01 AI069924NIAMS NIH HHS R01 AR080194NIMH NIH HHS R01 MH126856
6 · The paper itself

Abstract

Importance: When randomized trials are unavailable or not feasible, observational studies can be used to answer causal questions about the comparative effects of interventions by attempting to emulate a hypothetical pragmatic randomized trial (target trial). Published guidance to aid reporting of these studies is not available. Objective: To develop consensus-based guidance for reporting observational studies performed to estimate causal effects by explicitly emulating a target trial. Design, Setting, and Participants: The Transparent Reporting of Observational Studies Emulating a Target Trial (TARGET) guideline was developed using the Enhancing the Quality and Transparency of Health Research (EQUATOR) framework. The development included (1) a systematic review of reporting practices in published studies that had explicitly aimed to emulate a target trial; (2) a 2-round online survey (August 2023 to March 2024; 18 expert participants from 6 countries) to assess the importance of candidate items selected from previous research and to identify additional items; (3) a 3-day expert consensus meeting (June 2024; 18 panelists) to refine the scope of the guideline and draft the checklist; and (4) pilot of the draft checklist with stakeholders (n = 108; September 2024 to February 2025). The checklist was further refined based on feedback on successive drafts. Findings: The 21-item TARGET checklist is organized into 6 sections (abstract, introduction, methods, results, discussion, other information). TARGET provides guidance for reporting observational studies of interventions explicitly emulating a parallel group, individually randomized target trial, with adjustment for baseline confounders. Key recommendations are to (1) identify the study as an observational emulation of a target trial; (2) summarize the causal question and reason for emulating a target trial, (3) clearly specify the target trial protocol (ie, the causal estimand, identifying assumptions, data analysis plan) and how it was mapped to the observational data, and (4) report the estimate obtained for each causal estimand, its precision, and findings from additional analyses to assess the sensitivity of the estimates to assumptions, and design and analysis choices. Conclusions and Relevance: Application of the TARGET guideline recommendations aims to improve reporting transparency and peer review and help researchers, clinicians, and other readers interpret and apply the results.

Indexed as

Guidelines as TopicObservational Studies as TopicResearch ReportChecklistConsensusHumansRandomized Controlled Trials as TopicResearch DesignSystematic Reviews as Topic

Identifiers

PMID40899949
PMCPMC13084563

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.